Federal Grant Award Summary

Singular Immune, Inc. received a $304,909 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships program (CFDA 47.084) effective July 1, 2026, with a completion date of June 30, 2027. The award funds development of a novel protein-based platform that enables Chimeric Antigen Receptor (CAR) generation in vivo without genetic modification of cells. Rather than inserting genetic material into immune cells, the project delivers pre-formed targeting proteins that temporarily program immune cells to recognize and eliminate disease targets. The research will evaluate the modularity of this protein platform by testing whether targeting components can be systematically adapted to different disease targets while maintaining overall functionality.

This technology has potential to reduce manufacturing complexity and costs associated with current engineered immune cell therapies, which can exceed hundreds of thousands of dollars per patient and require specialized facilities. By leveraging established protein production methods, the approach aims to increase accessibility of advanced immune therapies in community hospitals and resource-limited settings. The platform has potential applications across cancer treatment, autoimmune diseases, and emerging infectious diseases, with the broader objective of enabling a new class of more affordable, rapidly adaptable, and broadly distributable immune treatments.